Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer.

Kuninty PR, Bansal R, De Geus SWL, Mardhian DF, Schnittert J, van Baarlen J, Storm G, Bijlsma MF, van Laarhoven HW, Metselaar JM, Kuppen PJK, Vahrmeijer AL, Östman A, Sier CFM, Prakash J.

Sci Adv. 2019 Sep 4;5(9):eaax2770. doi: 10.1126/sciadv.aax2770. eCollection 2019 Sep.

PMID:
31517053
2.

A method for semi-automated image analysis of HLA class I tumour epithelium expression in rectal cancer.

Krijgsman D, Van Vlierberghe RLP, Evangelou V, Vahrmeijer AL, Van de Velde CJH, Sier CFM, Kuppen PJK.

Eur J Histochem. 2019 May 20;63(2). doi: 10.4081/ejh.2019.3028.

3.

Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer.

Sandberg TP, Stuart MPME, Oosting J, Tollenaar RAEM, Sier CFM, Mesker WE.

BMC Cancer. 2019 Mar 29;19(1):284. doi: 10.1186/s12885-019-5462-2.

4.

Fluorescence-guided tumor detection with a novel anti-EpCAM targeted antibody fragment: Preclinical validation.

Boogerd LSF, Boonstra MC, Prevoo HAJM, Handgraaf HJM, Kuppen PJK, van de Velde CJH, Fish A, Cordfunke RA, Valentijn ARPM, Terwisscha van Scheltinga AG, MacDonald GC, Cizeau J, Premsukh A, Vinkenburg van Slooten ML, Burggraaf J, Sier CFM, Vahrmeijer AL.

Surg Oncol. 2019 Mar;28:1-8. doi: 10.1016/j.suronc.2018.10.004. Epub 2018 Oct 23.

PMID:
30851880
5.

Introducing fluorescence guided surgery into orthopedic oncology: A systematic review of candidate protein targets for Ewing sarcoma.

Bosma SE, van Driel PB, Hogendoorn PC, Dijkstra PS, Sier CF.

J Surg Oncol. 2018 Nov;118(6):906-914. doi: 10.1002/jso.25224. Epub 2018 Sep 13. Review.

6.

Endoglin Expression on Cancer-Associated Fibroblasts Regulates Invasion and Stimulates Colorectal Cancer Metastasis.

Paauwe M, Schoonderwoerd MJA, Helderman RFCP, Harryvan TJ, Groenewoud A, van Pelt GW, Bor R, Hemmer DM, Versteeg HH, Snaar-Jagalska BE, Theuer CP, Hardwick JCH, Sier CFM, Ten Dijke P, Hawinkels LJAC.

Clin Cancer Res. 2018 Dec 15;24(24):6331-6344. doi: 10.1158/1078-0432.CCR-18-0329. Epub 2018 Jun 26.

PMID:
29945992
7.

Biomarker expression in rectal cancer tissue before and after neoadjuvant therapy.

Boogerd LS, van der Valk MJ, Boonstra MC, Prevoo HA, Hilling DE, van de Velde CJ, Sier CF, Fariña Sarasqueta A, Vahrmeijer AL.

Onco Targets Ther. 2018 Mar 23;11:1655-1664. doi: 10.2147/OTT.S145473. eCollection 2018.

8.

Fluorescence- and multispectral optoacoustic imaging for an optimized detection of deeply located tumors in an orthotopic mouse model of pancreatic carcinoma.

Napp J, Stammes MA, Claussen J, Prevoo HAJM, Sier CFM, Hoeben FJM, Robillard MS, Vahrmeijer AL, Devling T, Chan AB, de Geus-Oei LF, Alves F.

Int J Cancer. 2018 May 15;142(10):2118-2129. doi: 10.1002/ijc.31236. Epub 2018 Jan 19.

9.

Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma.

Tummers WS, Farina-Sarasqueta A, Boonstra MC, Prevoo HA, Sier CF, Mieog JS, Morreau J, van Eijck CH, Kuppen PJ, van de Velde CJ, Bonsing BA, Vahrmeijer AL, Swijnenburg RJ.

Oncotarget. 2017 May 26;8(34):56816-56828. doi: 10.18632/oncotarget.18232. eCollection 2017 Aug 22.

10.

In Search for Optimal Targets for Intraoperative Fluorescence Imaging of Peritoneal Metastasis From Colorectal Cancer.

Hoogstins CE, Weixler B, Boogerd LS, Hoppener DJ, Prevoo HA, Sier CF, Burger JW, Verhoef C, Bhairosingh S, Farina Sarasqueta A, Burggraaf J, Vahrmeijer AL.

Biomark Cancer. 2017 Aug 28;9:1179299X17728254. doi: 10.1177/1179299X17728254. eCollection 2017.

11.

Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells.

de Geus SW, Baart VM, Boonstra MC, Kuppen PJ, Prevoo HA, Mazar AP, Bonsing BA, Morreau H, van de Velde CJ, Vahrmeijer AL, Sier CF.

Biomark Insights. 2017 Jun 22;12:1177271917715443. doi: 10.1177/1177271917715443. eCollection 2017. Review.

12.

Correlation Between Preoperative Serum Carcinoembryonic Antigen Levels and Expression on Pancreatic and Rectal Cancer Tissue.

Boogerd LSF, Vuijk FA, Hoogstins CES, Handgraaf HJM, van der Valk MJM, Kuppen PJK, Sier CFM, van de Velde CJH, Burggraaf J, Fariña-Sarasqueta A, Vahrmeijer AL.

Biomark Cancer. 2017 May 17;9:1179299X17710016. doi: 10.1177/1179299X17710016. eCollection 2017.

13.

uPAR directed-imaging of head-and-neck cancer.

Baart VM, Boonstra MC, Sier CFM.

Oncotarget. 2017 Mar 28;8(13):20519-20520. doi: 10.18632/oncotarget.16240. No abstract available.

14.

Real-time near-infrared fluorescence imaging using cRGD-ZW800-1 for intraoperative visualization of multiple cancer types.

Handgraaf HJM, Boonstra MC, Prevoo HAJM, Kuil J, Bordo MW, Boogerd LSF, Sibinga Mulder BG, Sier CFM, Vinkenburg-van Slooten ML, Valentijn ARPM, Burggraaf J, van de Velde CJH, Frangioni JV, Vahrmeijer AL.

Oncotarget. 2017 Mar 28;8(13):21054-21066. doi: 10.18632/oncotarget.15486.

15.

Morphological and phenotypical features of ovarian metastases in breast cancer patients.

Peters IT, van der Steen MA, Huisman BW, Hilders CG, Smit VT, Vahrmeijer AL, Sier CF, Trimbos JB, Kuppen PJ.

BMC Cancer. 2017 Mar 21;17(1):206. doi: 10.1186/s12885-017-3191-y.

16.

Preclinical uPAR-targeted multimodal imaging of locoregional oral cancer.

Boonstra MC, Van Driel PBAA, Keereweer S, Prevoo HAJM, Stammes MA, Baart VM, Löwik CWGM, Mazar AP, van de Velde CJH, Vahrmeijer AL, Sier CFM.

Oral Oncol. 2017 Mar;66:1-8. doi: 10.1016/j.oraloncology.2016.12.026. Epub 2017 Jan 4.

PMID:
28249642
17.

Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery.

Stammes MA, Prevoo HA, Ter Horst MC, Groot SA, Van de Velde CJ, Chan AB, de Geus-Oei LF, Kuppen PJ, Vahrmeijer AL, Pasquale EB, Sier CF.

Int J Mol Sci. 2017 Feb 3;18(2). pii: E307. doi: 10.3390/ijms18020307.

18.

EpCAM as multi-tumour target for near-infrared fluorescence guided surgery.

van Driel PB, Boonstra MC, Prevoo HA, van de Giessen M, Snoeks TJ, Tummers QR, Keereweer S, Cordfunke RA, Fish A, van Eendenburg JD, Lelieveldt BP, Dijkstra J, van de Velde CJ, Kuppen PJ, Vahrmeijer AL, Löwik CW, Sier CF.

BMC Cancer. 2016 Nov 14;16(1):884.

19.

Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery.

de Geus SW, Boogerd LS, Swijnenburg RJ, Mieog JS, Tummers WS, Prevoo HA, Sier CF, Morreau H, Bonsing BA, van de Velde CJ, Vahrmeijer AL, Kuppen PJ.

Mol Imaging Biol. 2016 Dec;18(6):807-819.

20.

Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins.

Boonstra MC, de Geus SW, Prevoo HA, Hawinkels LJ, van de Velde CJ, Kuppen PJ, Vahrmeijer AL, Sier CF.

Biomark Cancer. 2016 Sep 27;8:119-133. eCollection 2016. Review.

21.

Identification of cell-surface markers for detecting breast cancer cells in ovarian tissue.

Peters IT, Hilders CG, Sier CF, Vahrmeijer AL, Smit VT, Baptist Trimbos J, Kuppen PJ.

Arch Gynecol Obstet. 2016 Aug;294(2):385-93. doi: 10.1007/s00404-016-4036-7. Epub 2016 Mar 5.

22.

Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer.

Paauwe M, Heijkants RC, Oudt CH, van Pelt GW, Cui C, Theuer CP, Hardwick JC, Sier CF, Hawinkels LJ.

Oncogene. 2016 Aug 4;35(31):4069-79. doi: 10.1038/onc.2015.509. Epub 2016 Jan 25.

PMID:
26804178
23.

Stromal Targets for Fluorescent-Guided Oncologic Surgery.

Boonstra MC, Prakash J, Van De Velde CJ, Mesker WE, Kuppen PJ, Vahrmeijer AL, Sier CF.

Front Oncol. 2015 Nov 20;5:254. doi: 10.3389/fonc.2015.00254. eCollection 2015. Review.

24.

Preclinical evaluation of a novel CEA-targeting near-infrared fluorescent tracer delineating colorectal and pancreatic tumors.

Boonstra MC, Tolner B, Schaafsma BE, Boogerd LS, Prevoo HA, Bhavsar G, Kuppen PJ, Sier CF, Bonsing BA, Frangioni JV, van de Velde CJ, Chester KA, Vahrmeijer AL.

Int J Cancer. 2015 Oct 15;137(8):1910-20. doi: 10.1002/ijc.29571. Epub 2015 Jun 22.

25.

uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgery.

Boonstra MC, van Driel PB, van Willigen DM, Stammes MA, Prevoo HA, Tummers QR, Mazar AP, Beekman FJ, Kuppen PJ, van de Velde CJ, Löwik CW, Frangioni JV, van Leeuwen FW, Sier CF, Vahrmeijer AL.

Oncotarget. 2015 Jun 10;6(16):14260-73.

26.

Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer.

Goossens-Beumer IJ, Zeestraten EC, Benard A, Christen T, Reimers MS, Keijzer R, Sier CF, Liefers GJ, Morreau H, Putter H, Vahrmeijer AL, van de Velde CJ, Kuppen PJ.

Br J Cancer. 2014 Jun 10;110(12):2935-44. doi: 10.1038/bjc.2014.226. Epub 2014 May 1.

27.

Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study.

Boonstra MC, Verbeek FP, Mazar AP, Prevoo HA, Kuppen PJ, van de Velde CJ, Vahrmeijer AL, Sier CF.

BMC Cancer. 2014 Apr 17;14:269. doi: 10.1186/1471-2407-14-269.

28.

Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer.

Blok EJ, Kuppen PJ, van Leeuwen JE, Sier CF.

Clin Med Insights Oncol. 2013;7:41-51. doi: 10.4137/CMO.S10811. Epub 2013 Feb 21.

29.

Bone healing and mannose-binding lectin.

Van der Ende J, Van Baardewijk LJ, Sier CF, Schipper IB.

Int J Surg. 2013;11(4):296-300. doi: 10.1016/j.ijsu.2013.02.022. Epub 2013 Mar 1. Review.

30.

Circulating bone morphogenetic protein levels and delayed fracture healing.

van Baardewijk LJ, van der Ende J, Lissenberg-Thunnissen S, Romijn LM, Hawinkels LJ, Sier CF, Schipper IB.

Int Orthop. 2013 Mar;37(3):523-7. doi: 10.1007/s00264-012-1750-z. Epub 2012 Dec 28.

31.

Interaction with colon cancer cells hyperactivates TGF-β signaling in cancer-associated fibroblasts.

Hawinkels LJ, Paauwe M, Verspaget HW, Wiercinska E, van der Zon JM, van der Ploeg K, Koelink PJ, Lindeman JH, Mesker W, ten Dijke P, Sier CF.

Oncogene. 2014 Jan 2;33(1):97-107. doi: 10.1038/onc.2012.536. Epub 2012 Dec 3.

PMID:
23208491
32.

Injury pattern, injury severity, and mortality in 33,495 hospital-admitted victims of motorized two-wheeled vehicle crashes in The Netherlands.

Leijdesdorff HA, Siegerink B, Sier CF, Reurings MC, Schipper IB.

J Trauma Acute Care Surg. 2012 May;72(5):1363-8. doi: 10.1097/TA.0b013e318250cced.

PMID:
22673267
33.

MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients.

Langers AM, Verspaget HW, Hawinkels LJ, Kubben FJ, van Duijn W, van der Reijden JJ, Hardwick JC, Hommes DW, Sier CF.

Br J Cancer. 2012 Apr 24;106(9):1495-8. doi: 10.1038/bjc.2012.80.

34.

Implant removal associated complications in children with limb fractures due to trauma.

Gorter EA, Vos DI, Sier CF, Schipper IB.

Eur J Trauma Emerg Surg. 2011 Dec;37(6):623-7. doi: 10.1007/s00068-011-0087-4. Epub 2011 Mar 17.

35.

Displaced midshaft fractures of the clavicle: non-operative treatment versus plate fixation (Sleutel-TRIAL). A multicentre randomised controlled trial.

Stegeman SA, de Jong M, Sier CF, Krijnen P, Duijff JW, van Thiel TP, de Rijcke PA, Soesman NM, Hagenaars T, Boekhoudt FD, de Vries MR, Roukema GR, Tanka AF, van den Bremer J, van der Meulen HG, Bronkhorst MW, van Dijkman BA, van Zutphen SW, Vos DI, Schep NW, Eversdijk MG, van Olden GD, van den Brand JG, Hillen RJ, Frölke JP, Schipper IB.

BMC Musculoskelet Disord. 2011 Aug 24;12:196. doi: 10.1186/1471-2474-12-196.

36.

Single-nucleotide polymorphisms of matrix metalloproteinases and their inhibitors in gastrointestinal cancer.

Langers AM, Verspaget HW, Hommes DW, Sier CF.

World J Gastrointest Oncol. 2011 Jun 15;3(6):79-98. doi: 10.4251/wjgo.v3.i6.79.

37.

Clinical applications of the urokinase receptor (uPAR) for cancer patients.

Boonstra MC, Verspaget HW, Ganesh S, Kubben FJ, Vahrmeijer AL, van de Velde CJ, Kuppen PJ, Quax PH, Sier CF.

Curr Pharm Des. 2011;17(19):1890-910. Review.

PMID:
21711239
38.

Use and efficacy of bone morphogenetic proteins in fracture healing.

Lissenberg-Thunnissen SN, de Gorter DJ, Sier CF, Schipper IB.

Int Orthop. 2011 Sep;35(9):1271-80. doi: 10.1007/s00264-011-1301-z. Epub 2011 Jun 23. Review.

39.

[The midshaft clavicular fracture].

Duijff JW, Sier CF, Schipper IB.

Ned Tijdschr Geneeskd. 2010;154:A2367. Review. Dutch.

PMID:
21083959
40.

Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis.

Hawinkels LJ, Kuiper P, Wiercinska E, Verspaget HW, Liu Z, Pardali E, Sier CF, ten Dijke P.

Cancer Res. 2010 May 15;70(10):4141-50. doi: 10.1158/0008-5472.CAN-09-4466. Epub 2010 Apr 27.

41.

Clinical significance of stromal apoptosis in colorectal cancer.

Koelink PJ, Sier CF, Hommes DW, Lamers CB, Verspaget HW.

Br J Cancer. 2009 Sep 1;101(5):765-73. doi: 10.1038/sj.bjc.6605220. Epub 2009 Aug 4.

42.

5-Aminosalicylic acid inhibits TGF-beta1 signalling in colorectal cancer cells.

Koelink PJ, Hawinkels LJ, Wiercinska E, Sier CF, ten Dijke P, Lamers CB, Hommes DW, Verspaget HW.

Cancer Lett. 2010 Jan 1;287(1):82-90. doi: 10.1016/j.canlet.2009.05.033. Epub 2009 Jun 21.

PMID:
19541409
43.

Active TGF-beta1 correlates with myofibroblasts and malignancy in the colorectal adenoma-carcinoma sequence.

Hawinkels LJ, Verspaget HW, van der Reijden JJ, van der Zon JM, Verheijen JH, Hommes DW, Lamers CB, Sier CF.

Cancer Sci. 2009 Apr;100(4):663-70.

44.

Expression of endoglin (CD105) in cervical cancer.

Zijlmans HJ, Fleuren GJ, Hazelbag S, Sier CF, Dreef EJ, Kenter GG, Gorter A.

Br J Cancer. 2009 May 19;100(10):1617-26. doi: 10.1038/sj.bjc.6605009. Epub 2009 Apr 7.

45.

VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis.

Hawinkels LJ, Zuidwijk K, Verspaget HW, de Jonge-Muller ES, van Duijn W, Ferreira V, Fontijn RD, David G, Hommes DW, Lamers CB, Sier CF.

Eur J Cancer. 2008 Sep;44(13):1904-13. doi: 10.1016/j.ejca.2008.06.031. Epub 2008 Aug 6.

PMID:
18691882
46.

Matrix metalloproteinases and their tissue inhibitors as prognostic indicators for diagnostic and surgical recurrence in Crohn's disease.

Meijer MJ, Mieremet-Ooms MA, Sier CF, van Hogezand RA, Lamers CB, Hommes DW, Verspaget HW.

Inflamm Bowel Dis. 2009 Jan;15(1):84-92. doi: 10.1002/ibd.20581.

PMID:
18634035
47.

MMP-2 geno-phenotype is prognostic for colorectal cancer survival, whereas MMP-9 is not.

Langers AM, Sier CF, Hawinkels LJ, Kubben FJ, van Duijn W, van der Reijden JJ, Lamers CB, Hommes DW, Verspaget HW.

Br J Cancer. 2008 Jun 3;98(11):1820-3. doi: 10.1038/sj.bjc.6604380. Epub 2008 May 27.

48.

Endothelium specific matrilysin (MMP-7) expression in human cancers.

Sier CF, Hawinkels LJ, Zijlmans HJ, Zuidwijk K, de Jonge-Muller ES, Ferreira V, Hanemaaijer R, Mulder-Stapel AA, Kenter GG, Verspaget HW, Gorter A.

Matrix Biol. 2008 Apr;27(3):267-71. Epub 2007 Oct 26.

PMID:
18023162
49.

Efficient degradation-aided selection of protease inhibitors by phage display.

Hawinkels LJ, van Rossenberg SM, de Jonge-Muller ES, Molenaar TJ, Appeldoorn CC, van Berkel TJ, Sier CF, Biessen EA.

Biochem Biophys Res Commun. 2007 Dec 21;364(3):549-55. Epub 2007 Oct 15.

PMID:
17959143
50.

Eradication of Helicobacter pylori infection favourably affects altered gastric mucosal MMP-9 levels.

Kubben FJ, Sier CF, Schram MT, Witte AM, Veenendaal RA, van Duijn W, Verheijen JH, Hanemaaijer R, Lamers CB, Verspaget HW.

Helicobacter. 2007 Oct;12(5):498-504.

PMID:
17760717

Supplemental Content

Support Center